piperidines and Migraine-without-Aura

Determine whether common migraine comorbidities affect the efficacy and safety of lasmiditan, a 5-HT. Across all the Comorbidity Groups, with the potential exception of fatigue, treatment-by-subgroup interaction analyses did not provide evidence of a lasmiditan-driven lasmiditan versus placebo differential treatment effect dependent on Yes versus No comorbidity subgroup for either efficacy or TEAE assessments.. The efficacy and safety of lasmiditan for treatment of individual migraine attacks appear to be independent of comorbid conditions.

Topics: Adult; Benzamides; Comorbidity; Dizziness; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine without Aura; Nausea; Piperidines; Pyridines; Serotonin Receptor Agonists; Treatment Outcome; Vertigo

Intractable migraine presents a significant treatment challenge to both patient and physician. Most attacks are treatable or self-limiting, but occasionally they may continue for extended periods regardless of treatment.. To determine the efficacy of naratriptan 2.5 mg twice daily for the treatment of intractable migraine.. We reviewed 24 patients treated with naratriptan twice daily for an intractable migraine attack. Patients were permitted to take prophylactic medication if such treatment had been effective in the past.. Nineteen patients (79%) improved. Twelve patients showed excellent response with cessation of pain and associated symptoms, 7 patients partially responded with lessening of pain and cessation of associated symptoms, and 5 patients were nonresponsive.. Short-term daily administration of naratriptan may be effective in terminating status migrainosus.

Topics: Adult; Female; Humans; Indoles; Middle Aged; Migraine without Aura; Piperidines; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines